Please ensure Javascript is enabled for purposes of website accessibility

Why Gilead Sciences Shares Rose 7.79% in March

By Adria Cimino - Apr 3, 2020 at 8:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The promise of Gilead’s coronavirus treatment lifted the shares.

What happened

Shares of Gilead Sciences (GILD 0.82%) rose 7.79% in March, according to data provided by S&P Global Market Intelligence, even as stocks moved into a bear market. Investors flocked to shares of companies developing treatments for COVID-19, the illness caused by the novel coronavirus.

Pills and a mask are set on a wooden surface with 'COVID-19' written on a piece of paper.

Image source: Getty Images.

The coronavirus outbreak has now reached 900,300 cases worldwide, and demand for Gilead's investigational treatment, remdesivir, has skyrocketed. Though the drug isn't approved for COVID-19 or any other indication, Gilead has been able to provide it to some patients based on a "compassionate use" program. A World Health Organization doctor said the treatment showed promise according to media reports earlier this year, and Gilead confirmed that remdesivir has been used in more than 1,000 patients so far.

So what

Since there isn't an approved treatment or vaccine for COVID-19, the promise of remdesivir has pushed Gilead to the forefront. The drug currently is involved in two phase 3 clinical studies to evaluate safety and efficacy.

However, if remdesivir is approved, it's unlikely to become a long-lasting blockbuster for Gilead. Addressing pandemics generally isn't extremely profitable for drugmakers over the long term. That is due to the short time frame of a pandemic and the ethical question of pricing a treatment too high. Still, the spotlight on Gilead may draw investors' attention to the company's robust pipeline and marketed products in areas including HIV and cardiovascular disease.

Now what

Investors, patients, and healthcare workers are eagerly waiting for the results of the remdesivir trials and an eventual regulatory approval. Any positive news will likely send the shares higher. For the long term, though, investors should monitor news on Gilead's rheumatoid arthritis treatment, filgotinib. The company submitted the drug to the U.S. Food and Drug Administration for review in December with a priority review voucher, which generally reduces review time to about six months from the standard of 10 months. A positive verdict there may be important for long-term gains in this biotech stock.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.96 (0.82%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.